Related Experiment Video
Updated: Jul 6, 2025

Surfactant Depletion Combined with Injurious Ventilation Results in a Reproducible Model of the Acute Respiratory Distress Syndrome ARDS
Published on: April 7, 2021
Hypoventilation in patients with Prader-Willi syndrome across the pediatric age
Catherine Chen1,2, Iulia Ioan3, Marine Thieux2,4,5
1Service de pneumologie pédiatrique, Hôpital Femme Mère Enfant, Hospices, Civils de Lyon, Bron, France.
Insights
Alveolar hypoventilation affects 35% of children with Prader-Willi syndrome (PWS), often without symptoms. Regular screening is recommended, especially with age and growth hormone (GH) treatment, to monitor respiratory health in PWS patients.
Area of Science:
- Pediatric Pulmonology
- Genetics
- Sleep Medicine
Background:
- Prader-Willi syndrome (PWS) is a complex genetic disorder with limited data on respiratory complications.
- Standardized respiratory follow-up for PWS patients is lacking, particularly concerning alveolar hypoventilation.
Purpose of the Study:
- To determine the prevalence of alveolar hypoventilation in children with PWS.
- To identify potential risk factors associated with alveolar hypoventilation in this population.
Main Methods:
- Retrospective polysomnography (PSG) study of children with PWS (2007-2021).
- Inclusion criteria: PSG with transcutaneous CO2 (PtcCO2) or end-tidal CO2 (ETCO2) measurements.
- Alveolar hypoventilation defined as pCO2 ≥ 50 mmHg for ≥2% of total sleep time or >5 consecutive minutes.
Main Results:
- 35% (20/57) of children with PWS exhibited alveolar hypoventilation.
- Median pCO2 max was 49 mmHg; 25% of hypoventilating children were asymptomatic.
- Higher median age and growth hormone (GH) treatment were associated with hypoventilation.
Conclusions:
- Alveolar hypoventilation is a significant concern in pediatric PWS, potentially increasing with age and GH therapy.
- Regular screening using oximetry-capnography is advised for all PWS patients, irrespective of sex, BMI, or apnea index.
Objectives:
Few data on alveolar hypoventilation in Prader-Willi syndrome (PWS) are available and the respiratory follow-up of these patients is not standardized. The objectives of this study were to evaluate the prevalence of alveolar hypoventilation in children with PWS and identify potential risk factors.
Study Design:
This retrospective study included children with PWS recorded by polysomnography (PSG) with transcutaneous carbon dioxide pressure (PtcCO2) or end-tidal CO2 (ETCO2) measurements, between 2007 and 2021, in a tertiary hospital center. The primary outcome was the presence of alveolar hypoventilation defined as partial pressure of carbon dioxide (pCO2) ≥ 50 mmHg during ≥2% of total sleep time (TST) or more than five consecutive minutes.
Results:
Among the 57 included children (38 boys, median age 4.8 years, range 0.1-15.6, 60% treated with growth hormone [GH], 37% obese), 19 (33%) had moderate-to-severe obstructive sleep apnea syndrome (defined as obstructive apnea-hypopnea index ≥5/h) and 20 (35%) had hypoventilation. The median (range) pCO2 max was 49 mmHg (38-69). Among the children with hypoventilation, 25% were asymptomatic. Median age and GH treatment were significantly higher in children with hypoventilation compared to those without. There was no significant difference in terms of sex, BMI, obstructive or central apnea-hypopnea index between both groups.
Conclusion:
The frequency of alveolar hypoventilation in children and adolescents with PWS is of concern and may increase with age and GH treatment. A regular screening by oximetry-capnography appears to be indicated whatever the sex, BMI, and rate of obstructive or central apneas.
Related Concept Videos
Alterations in Respiration II
In Biot's breathing, the respiratory rate and depth are irregular, alternating between periods of deep gasping and apnea. Common causes...
Hyperpnea and Hyperventilation
Pulmonary Cycle: Exhalation
Acute Respiratory Failure-II
The underlying physiological abnormalities that contribute to hypoxemic respiratory failure include:
Acute Respiratory Failure-III
Acute Respiratory Failure-IV

